Persistence of Increased Eotaxin-1 (CCL11) Level in Tears of Patients Wearing Contact Lenses: A Long-Term Follow-Up Study

Zusammenfassung

Hintergrund: Eotaxin-1 (CCL11) ist ein chemotaktisches eosinophiles Agens und Aktivator-Peptid in der Tränenflüssigkeit von Kontaktlinsenträgern (KL). Ziel der Studie ist, die Langzeit-Expression von CCL11 bei KL-Trägern zu untersuchen. Patienten und Methoden: Bei 15 Patienten, die Kontaktlinsen tragen, wurden 15 µL Tränenflüssigkeit gesammelt im Intervall von 2 Jahren. Der Schweregrad (0 – 4) der kontaktlinseninduzierten Konjunktivitis (CLPC) wurde anhand der superioren conjunctiva tarsi bestimmt und die Konzentration von CCL11 mittels ELISA bestimmt. Ergebnisse: Das Durchschnittsalter der Patienten betrug 32,5 Jahre. Die durchschnittliche Zeit zwischen den beiden Tränenproben betrug 30 Monate, die durchschnittliche CCL11-Konzentration 2150 und 2486 pg/mL, der Schweregrad der CLPC 1,26 und 1,40. Obschon sich die Konzentration von CCL11 und der Schweregrad der CLPC nach 2 Jahren verschlimmert haben, sind die Differenzen nicht signifikant (paired Wilcoxon/Kruskal-Wallis, jeweils p = 0,803 und p = 0,751). Schlussfolgerungen: Die Konzentration von CCL11 bleibt bei KL-Trägern, welche an chronischer CLPC oft leiden, langfristig hoch. CCL11 könnte eine Rolle in der Pathogenese der Kontaktlinsen-Intoleranz spielen.

Abstract

Background: Eotaxin-1 (CCL11) is a potent eosinophil chemotactic and activating peptide that may be implicated in the pathogenesis of chronic allergic eye disease and has been associated with the wearing of contact lenses (CL) in patients with contact lens papillary conjunctivitis (CLPC). The purpose of this study was to study eotaxin-1 expression in the tears of long-term CL wearers. Patients and Methods: Tears were collected with glass capillaries from 15 patients (2 male, 13 female) with various degree of CLPC at 2-year intervals. CLPC severity was graded from 0 to 4 with reference to standard slit-lamp photographs of the superior tarsal conjunctiva. The eotaxin-1 level in the tears was measured by an ELISA, using mouse anti-human eotaxin monoclonal antibodies. Results: The mean age was 32.5 ± 13.3 years (range: 17 – 69 years). The mean interval between the tear collections was 30 ± 4.8 months. The mean concentration of eotaxin was 2150 ± 477 pg/mL and 2486 ± 810 pg/mL for the first and second series, respectively. The difference was not statistically significant (paired Wilcoxon/Kruskal-Wallis, p = 0.803). The mean score of papilla grade was 1.26 ± 0.18 for the first sample and 1.40 ± 0.19 two years later. There was no significant difference of grading between the two time periods (paired Wilcoxon/Kruskal-Wallis, p = 0.751). Conclusions: the eotaxin-1 level remains up-regulated over a long time period in patients wearing CL, most of them with chronic CLPC. Eotaxin may play a role in the pathogenesis of contact lens intolerance.

Schlüsselwörter

Eotaxin - Kontaktlinsen - Tränenflüssigkeit - Konjunktiva

Key words

eotaxin - contact lens - tears - conjunctiva

References

• 1 Jose P J, Griffiths-Johnson D A, Collins P D et al. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation.  J Exp Med. 1994;  179 881-887
• 2 Daugherty B L, Siciliano S J, DeMartino J A et al. Cloning, expression, and characterization of the human eosinophil eotaxin receptor.  J Exp Med. 1996;  183 2349-2354
• 3 Fukagawa K, Nakajima T, Tsubota K et al. Presence of eotaxin in tears of patients with atopic keratoconjunctivitis with severe corneal damage.  J Allergy Clin Immunol. 1999;  103 1220-1221
• 4 Leonardi A, Borghesan F, Faggian D et al. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases.  Am J Ophthalmol. 2000;  129 151-158
• 5 Moschos M M, Eperon S, Guex-Crosier Y. Increased eotaxin in tears of patients wearing contact lenses.  Cornea. 2004;  23 771-775
• 6 Trocme S D, Kephart G M, Allansmith M R et al. Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis.  Am J Ophthalmol. 1989;  108 57-63
• 7 Sankaridurg P R, Sweeney D F, Sharma S et al. Adverse events with extended wear of disposable hydrogels: results for the first 13 months of lens wear.  Ophthalmology. 1999;  106 1671-1680
• 8 Levy B, McNamara N, Corzine J et al. Prospective trial of daily and extended wear disposable contact lens.  Cornea. 1997;  16 274-276 ; erratum in: Cornea 1997; 16: 600
• 9 Allansmith M R, Korb D R, Greiner J V et al. Giant papillary conjunctivitis in contact lens wearers.  Am J Ophthalmol. 1977;  83 697-708
• 10 Elgebaly S A, Donshik P C, Rahhal F et al. Neutrophil chemotactic factors in the tears of giant papillary conjunctivitis patients.  Invest Ophthalmol Vis Sci. 1991;  32 208-213
• 11 Mathers W D, Billborough M. Meibomian gland function and giant papillary conjunctivitis.  Am J Ophthalmol. 1992;  114 188-192
• 12 Metz D P, Hingorani M, Calder V L et al. T-cell cytokines in chronic allergic eye disease.  J Allergy Clin Immunol. 1997;  100 817-824
• 13 Woods R L. Quantitative slit lamp observations in contact lens practice.  J Br Contact Lens Assoc (Scientific Meetings). 1989;  12 42-45
• 14 Trocme S D, Aldave A J. The eye and the eosinophil.  Surv Ophthalmol. 1994;  39 241-252
• 15 Forssmann U, Uguccioni M, Loetscher P et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes.  J Exp Med. 1997;  185 2171-2176
• 16 Eperon S, Sauty A, Lanz R et al. Eotaxin-1 (CCL11) up-regulation in tears during seasonal allergic conjunctivitis.  Graefes Arch Clin Exp Ophthalmol. 2004;  242 966-970
• 17 Donshik P C. Giant papillary conjunctivitis.  Trans Am Ophthalmol Soc. 1994;  92 687-744
• 18 Skotnitsky C, Sankaridurg P R, Sweeney D F et al. General and local contact lens induced papillary conjunctivitis (CLPC).  Clin Exp Optom. 2002;  85 193-197